Breathe Easy is a Kiwi company that is developing an inhaled medicine called Citramel™ for the treatment of cystic fibrosis, and is currently raising funds for Phase I/IIa clinical trials through equity crowdfunding platform Snowball Effect.
Brent Ogilvie, Director of Breathe Easy, says the opportunity for the public to make small investments into this is unique.
“Our partnership with Snowball Effect means that people can invest amounts appropriate for them into this opportunity. Breathe Easy offers high potential financial and social returns for those who want to make a difference. With this, of course, comes high risk, but the potential to join a New Zealand driven team committed to combating cystic fibrosis has real appeal.”
Citramel™ addresses an estimated US$1 billion market and has been developed by Professor Bob Elliott, inventor and founder whose research also started Living Cell Technologies (ASX:LCT) and Somnaceutics (start-up to exit in 3 years).
Breathe Easy is seeking $2 million, of which it has already raised over $1 million from the NZ angel investor community, Pacific Channel, and the New Zealand Venture Investment Fund. Breathe Easy now seeks to raise up to $700,000 through Snowball Effect. This makes it New Zealand’s first wholesale investor / equity crowdfunding co-investment opportunity.